tetano
Editor, Senior Moderator
EClinicalMedicine
. 2020 Oct 13;100549.
doi: 10.1016/j.eclinm.2020.100549. Online ahead of print.
Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study
Sylvain Lamure[SUP] 1 [/SUP], R?my Dul?ry[SUP] 2 [/SUP], Roberta Di Blasi[SUP] 3 [/SUP], Adrien Chauchet[SUP] 4 [/SUP], C?cile Laureana[SUP] 5 [/SUP], B?n?dicte Deau-Fischer[SUP] 6 [/SUP], Bernard Drenou[SUP] 7 [/SUP], Carole Soussain[SUP] 8 [/SUP], C?dric Rossi[SUP] 9 [/SUP], Nicolas No?l[SUP] 10 [/SUP], Sylvain Choquet[SUP] 11 [/SUP], Serge Bologna[SUP] 12 [/SUP], Bertrand Joly[SUP] 13 [/SUP], Milena Kohn[SUP] 5 [/SUP], Sandra Malak[SUP] 8 [/SUP], Guillemette Fouquet[SUP] 6 [/SUP], Etienne Daguindau[SUP] 4 [/SUP], Sophie Bernard[SUP] 3 [/SUP], Catherine Thi?blemont[SUP] 3 [/SUP], Guillaume Cartron[SUP] 1 [/SUP], Karine Lacombe[SUP] 14 [/SUP], Caroline Besson[SUP] 5 15 [/SUP]
Affiliations
Abstract
Background: Patients with lymphoma are immunocompromised because of the disease per se and its treatments. We aimed to describe the characteristics of patients with lymphoma hospitalized for Coronavirus Disease 2019 (Covid-19) and to analyze pre-Covid-19 determinants of mortality.
Methods: This retrospective multicentric cohort study used the Programme de M?dicalisation des Syst?mes d'Information database to identify all adult patients with lymphoma, hospitalized for Covid-19 in March and April 2020, in 12 hospitals of three French regions with pandemic outbreaks. The characteristics of lymphoma and Covid-19 were collected from medical charts.
Findings: Eighty-nine patients were included. The median age was 67 years (range, 19-92), 66% were male and 72% had a comorbidity. Most patients had B-cell non-Hodgkin lymphoma (86%) and had received a lymphoma treatment within one year (70%). With a median follow-up of 33 days from admission, 30-day overall survival was 71%, (95% confidence interval, 62-81%). In multivariable analysis, having an age ≥ 70 years (hazard ratio 2?87, 1?20-6?85, p = 0?02) and relapsed/refractory lymphoma (hazard ratio 2?54, 1?14-5?66, p = 0?02) were associated with mortality. Recent bendamustine treatment (n = 9) was also pejorative (hazard ratio 3?20, 1?33-7?72, p = 0?01), but was strongly associated with relapsed/refractory lymphoma. Remarkably, 30-day overall survival for patients < 70 years of age without relapsed/refractory lymphoma was 88% (78% - 99%).
Interpretation: Thirty-day mortality was associated with being older and relapsed/refractory lymphoma. Survival of patients younger than 70 years without relapsed/refractory lymphoma was comparable to that of the general population.
Funding: There have been no specific funds to run this study.
. 2020 Oct 13;100549.
doi: 10.1016/j.eclinm.2020.100549. Online ahead of print.
Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study
Sylvain Lamure[SUP] 1 [/SUP], R?my Dul?ry[SUP] 2 [/SUP], Roberta Di Blasi[SUP] 3 [/SUP], Adrien Chauchet[SUP] 4 [/SUP], C?cile Laureana[SUP] 5 [/SUP], B?n?dicte Deau-Fischer[SUP] 6 [/SUP], Bernard Drenou[SUP] 7 [/SUP], Carole Soussain[SUP] 8 [/SUP], C?dric Rossi[SUP] 9 [/SUP], Nicolas No?l[SUP] 10 [/SUP], Sylvain Choquet[SUP] 11 [/SUP], Serge Bologna[SUP] 12 [/SUP], Bertrand Joly[SUP] 13 [/SUP], Milena Kohn[SUP] 5 [/SUP], Sandra Malak[SUP] 8 [/SUP], Guillemette Fouquet[SUP] 6 [/SUP], Etienne Daguindau[SUP] 4 [/SUP], Sophie Bernard[SUP] 3 [/SUP], Catherine Thi?blemont[SUP] 3 [/SUP], Guillaume Cartron[SUP] 1 [/SUP], Karine Lacombe[SUP] 14 [/SUP], Caroline Besson[SUP] 5 15 [/SUP]
Affiliations
- PMID: 33073216
- PMCID: PMC7550257
- DOI: 10.1016/j.eclinm.2020.100549
Abstract
Background: Patients with lymphoma are immunocompromised because of the disease per se and its treatments. We aimed to describe the characteristics of patients with lymphoma hospitalized for Coronavirus Disease 2019 (Covid-19) and to analyze pre-Covid-19 determinants of mortality.
Methods: This retrospective multicentric cohort study used the Programme de M?dicalisation des Syst?mes d'Information database to identify all adult patients with lymphoma, hospitalized for Covid-19 in March and April 2020, in 12 hospitals of three French regions with pandemic outbreaks. The characteristics of lymphoma and Covid-19 were collected from medical charts.
Findings: Eighty-nine patients were included. The median age was 67 years (range, 19-92), 66% were male and 72% had a comorbidity. Most patients had B-cell non-Hodgkin lymphoma (86%) and had received a lymphoma treatment within one year (70%). With a median follow-up of 33 days from admission, 30-day overall survival was 71%, (95% confidence interval, 62-81%). In multivariable analysis, having an age ≥ 70 years (hazard ratio 2?87, 1?20-6?85, p = 0?02) and relapsed/refractory lymphoma (hazard ratio 2?54, 1?14-5?66, p = 0?02) were associated with mortality. Recent bendamustine treatment (n = 9) was also pejorative (hazard ratio 3?20, 1?33-7?72, p = 0?01), but was strongly associated with relapsed/refractory lymphoma. Remarkably, 30-day overall survival for patients < 70 years of age without relapsed/refractory lymphoma was 88% (78% - 99%).
Interpretation: Thirty-day mortality was associated with being older and relapsed/refractory lymphoma. Survival of patients younger than 70 years without relapsed/refractory lymphoma was comparable to that of the general population.
Funding: There have been no specific funds to run this study.